

Studies Included at Full Text

Contextual Questions

1. Adams HJ, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. *Annals of hematology* 2016b;95:695-706. <https://link.springer.com/article/10.1007/s00277-016-2619-9>.
2. Adams HJ, Kwee TC. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. *Critical reviews in oncology/hematology* 2016c;106:55-63. [https://www.croh-online.com/article/S1040-8428\(16\)30158-5/fulltext](https://www.croh-online.com/article/S1040-8428(16)30158-5/fulltext).
3. Adams HJ, Kwee TC. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis. *European journal of haematology* 2017b;98:337-47. <https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.12837>.
4. Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Nievelstein RA. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. *European journal of nuclear medicine and molecular imaging* 2014;41:565-74. <https://www.ncbi.nlm.nih.gov/pubmed/24281821>.
5. Adams HJ, Nievelstein RA, Kwee TC. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis. *Pediatric hematology and oncology* 2015a;32:515-24. <https://www.ncbi.nlm.nih.gov/pubmed/26561044>.
6. Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. *British journal of haematology* 2015b;170:185-91. <https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13420>.
7. Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. *Annals of hematology* 2016d;95:11-8. <https://www.ncbi.nlm.nih.gov/pubmed/26576560>.
8. Adams HJ, Nievelstein RA, Kwee TC. Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma. *J Comput Assist Tomogr* 2017a;41:98-103. doi: 10.1097/RCT.0000000000000485. <https://www.ncbi.nlm.nih.gov/pubmed/27560022>.
9. Adams HJA, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis. *European journal of radiology* 2016a;85:1963-70. <https://www.ncbi.nlm.nih.gov/pubmed/27776647>.
10. Bakhshi S, Bhethanabhotla S, Kumar R, et al. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging. *J Nucl Med* 2017;58:577-83. doi: 10.2967/jnumed.116.176511. Epub 2016 Oct 6. <http://jnm.snmjournals.org/content/58/4/577.short>.

11. Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. *Blood* 2016;127:1531-8. doi: 10.182/blood-2015-11-679407. Epub 2016 Jan 8. <https://www.ncbi.nlm.nih.gov/pubmed/26747247>.
12. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* 2013;54:683-90. <https://www.ncbi.nlm.nih.gov/pubmed/23516309>.
13. Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. *Clin Nucl Med* 2011;36:553-9. <https://www.ncbi.nlm.nih.gov/pubmed/21637057>.
14. Cheng G, Alavi A. Value of 18F-FDG PET versus iliac biopsy in the initial evaluation of bone marrow infiltration in the case of Hodgkin's disease: a meta-analysis. *Nuclear medicine communications* 2013;34:25-31. <https://www.ncbi.nlm.nih.gov/pubmed/23111383>.
15. Cohen JB, Behera M, Thompson CA, Flowers CR. Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. *Blood* 2016;129:685073. <https://www.ncbi.nlm.nih.gov/pubmed/27956385>.
16. Cohen JB, Behera M, Thompson CA, Flowers CR. Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. *Blood* 2017;129:561-4. <https://www.ncbi.nlm.nih.gov/pubmed/27956385>.
17. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. *Health technology assessment (Winchester, England)* 2007;11:iii-iv, xi-267. <https://www.ncbi.nlm.nih.gov/pubmed/17999839>.
18. Fitzpatrick JJ, Ryan MA, Bruzzi JF. Diagnostic accuracy of diffusion-weighted imaging-magnetic resonance imaging compared to positron emission tomography/computed tomography in evaluating and assessing pathological response to treatment in adult patients with lymphoma: A systematic review. *Journal of medical imaging and radiation oncology* 2018. <https://www.ncbi.nlm.nih.gov/pubmed/29577630>.
19. Furth C, Amthauer H, Hautzel H, et al. Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read. *Annals of oncology : official journal of the European Society for Medical Oncology* 2011;22:1198-203. <https://www.ncbi.nlm.nih.gov/pubmed/20966182>.
20. Furth C, Erdreich AS, Steffen IG, et al. Interim PET response criteria in paediatric non-Hodgkin's lymphoma. Results from a retrospective multicenter reading. *Nuklearmedizin Nuclear medicine* 2013;52:148-56. <https://www.ncbi.nlm.nih.gov/pubmed/23928982>.
21. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. *Haematologica* 2014;99:1107-13. <https://www.ncbi.nlm.nih.gov/pubmed/24658820>.
22. Han EJ, O JH, Yoon H, et al. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome. *Medicine (Baltimore)* 2016;95:e4983. doi: 10.1097/MD.0000000000004983. <https://www.ncbi.nlm.nih.gov/pubmed/27684851>.

23. Kirby AM, George Mikhaeel N. The role of FDG PET in the management of lymphoma: practical guidelines. *Nuclear medicine communications* 2007;28:355-7. <https://www.ncbi.nlm.nih.gov/pubmed/17414884>.
24. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidence base? *Nuclear medicine communications* 2007;28:335-54. <https://www.ncbi.nlm.nih.gov/pubmed/17414883>.
25. Kluge R, Chavdarova L, Hoffmann M, et al. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma. *PLoS One* 2016;11:e0149072. doi: 10.1371/journal.pone.. eCollection 2016. <https://www.ncbi.nlm.nih.gov/pubmed/26963909>.
26. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. *Blood* 2008;111:504-16. <https://www.ncbi.nlm.nih.gov/pubmed/17916746>.
27. Liao C-C, Qin Y-Y, Tan X-H, et al. Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin's lymphoma. *OncoTargets and therapy* 2017;10:5727. <https://www.ncbi.nlm.nih.gov/pubmed/29238205>.
28. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* 2005;46:958-63. <https://www.ncbi.nlm.nih.gov/pubmed/15937306>.
29. Pyo J, Kim KW, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. *Clinical Cancer Research* 2013;19:6566-77. <https://www.ncbi.nlm.nih.gov/pubmed/24052020>.
30. Sawan P, Rebeiz K, Schoder H, et al. Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management. *Medicine (Baltimore)* 2017;96:e9411. doi: 10.1097/MD.0000000000009411. <https://www.ncbi.nlm.nih.gov/pubmed/29390562>.
31. Sun N, Zhao J, Qiao W, Wang T. Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis. *BioMed research international* 2015;2015:648572. <https://www.ncbi.nlm.nih.gov/pubmed/25710013>.
32. Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. *The oncologist* 2010;15:750-9. <https://www.ncbi.nlm.nih.gov/pubmed/20587551>.
33. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009;27:1906-14. <https://www.ncbi.nlm.nih.gov/pubmed/19273713>.
34. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. *Journal of nuclear medicine* 2008;49:13. <https://www.ncbi.nlm.nih.gov/pubmed/18077527>.
35. Toriihara A, Nakadate M, Nakamura S, Kubota K, Tateishi U. Seventy FDG-PET/CT cases in which nuclear medicine physicians suspected lymphoma: How reliable are we? *Asia Oceania Journal of*

- Nuclear Medicine and Biology 2017;5:95.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482924/>.
36. Uslu L, Donig J, Link M, Rosenberg J, Quon A, Daldrup-Link HE. Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. 2015. <https://www.ncbi.nlm.nih.gov/pubmed/25572088>.
 37. Wang C, Li P, Wu S, et al. The role of fluorine-18 fluorodeoxyglucose PET in prognosis evaluation for stem cell transplantation of lymphoma: a systematic review and meta-analysis. Nuclear medicine communications 2016;37:338-47. <https://www.ncbi.nlm.nih.gov/pubmed/26741290>.
 38. Wu LM, Chen FY, Jiang XX, Gu HY, Yin Y, Xu JR. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. European journal of radiology 2012;81:303-11. <https://www.ncbi.nlm.nih.gov/pubmed/21145680>.
 39. Yang M, Sun J, Bai HX, et al. Diagnostic accuracy of SPECT, PET, and MRS for primary central nervous system lymphoma in HIV patients: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6676. doi: 10.1097/MD.0000000000006676. <https://www.ncbi.nlm.nih.gov/pubmed/28489744>.
 40. Zhou X, Lu K, Geng L, Li X, Jiang Y, Wang X. Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma: a systematic review and meta-analysis. Medicine (Baltimore) 2014;93:e258. doi: 10.1097/MD.0000000000000258. <https://www.ncbi.nlm.nih.gov/pubmed/25526450>.
 41. Zhu Y, Lu J, Wei X, Song S, Huang G. The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis. BioMed research international 2013;2013. <https://www.ncbi.nlm.nih.gov/pubmed/24288671>.
 42. Ziakas PD, Poulou LS, Voulgarelis M, Thanos L. The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies. Leukemia & lymphoma 2012;53:2166-74. <https://www.ncbi.nlm.nih.gov/pubmed/22512238>.
 43. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen, II, Huijgens PC. 18F-fluorodeoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006;91:522-9. <https://www.ncbi.nlm.nih.gov/pubmed/16585017>.
 44. Zou Y, Tong J, Leng H, Jiang J, Pan M, Chen Z. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis. Oncotarget 2017;8:41518-28. doi: 10.18632/oncotarget.7456. <https://www.ncbi.nlm.nih.gov/pubmed/28514747>.

Evidence Base

1. Abou-Nassar KE, Vanderplas A, Friedberg JW, et al. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. *Leukemia & lymphoma* 2013;54:2155-62. <https://www.tandfonline.com/doi/full/10.3109/10428194.2013.770151>.
2. Andre MPE, Girinsky T, Federico M, et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. *J Clin Oncol* 2017;35:1786-94. doi: 10.200/JCO.2016.68.6394. Epub 2017 Mar 14. <https://www.ncbi.nlm.nih.gov/pubmed/28291393>.
3. Angelopoulou MK, Mosa E, Pangalis GA, et al. The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. *Anticancer Res* 2017;37:5727-36. <https://www.ncbi.nlm.nih.gov/pubmed/28982893>.
4. Awan UE, Siddiqui N, SaadUllah M, et al. FDG-PET scan in assessing lymphomas and the application of Deauville Criteria. *JPMA The Journal of the Pakistan Medical Association* 2013;63:725-30. <https://www.ncbi.nlm.nih.gov/pubmed/23901673>.
5. Bakhshi S, Radhakrishnan V, Sharma P, et al. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study. *Radiology* 2012;262:956-68. <https://www.ncbi.nlm.nih.gov/pubmed/22357895>.
6. Bednaruk-Mlynski E, Pienkowska J, Skorzak A, et al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. *Leukemia & lymphoma* 2015;56:377-82. <https://www.tandfonline.com/doi/full/10.3109/10428194.2014.919635>.
7. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *The Lancet* 2017b;390:2790-802. <https://www.sciencedirect.com/science/article/pii/S0140673617321347>.
8. Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. *Lancet Oncol* 2017a;18:454-63. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(17\)30103-1/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext).
9. Carras S, Dubois B, Senecal D, et al. Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial. *Clin Lymphoma Myeloma Leuk* 2018;18:191-8. doi: 10.1016/j.clml.2018.01.003. Epub Jan 31. [https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650\(17\)31620-8/fulltext](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)31620-8/fulltext).
10. Carrillo-Cruz E, Marin-Oyaga VA, de la Cruz Vicente F, et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. *Hematol Oncol* 2015;33:151-8. doi: 10.1002/hon.2181. Epub 014 Nov 19. <https://www.ncbi.nlm.nih.gov/pubmed/25407794>.
11. Casasnovas RO, Ysebaert L, Thieblemont C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. *Blood* 2017;130:1315-26. doi:

- 10.182/blood-2017-02-766691. Epub 2017 Jul 12.
<http://www.bloodjournal.org/content/130/11/1315.long>.
12. Casulo C, Schoder H, Feeney J, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. *Leukemia & lymphoma* 2013;54:2163-7.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915724/pdf/nihms537111.pdf>.
 13. Cheah CY, Dickinson M, Hofman MS, et al. Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. *Annals of hematology* 2014;93:1193-200.
<https://link.springer.com/article/10.1007%2Fs00277-014-2040-1>.
 14. Cheng G, Servaes S, Zhuang H. Value of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma. *Leukemia & lymphoma* 2013;54:737-42.
<https://www.tandfonline.com/doi/full/10.3109/10428194.2012.727416>.
 15. Crowley MP, O'Neill SB, Kevane B, et al. Ionizing radiation exposure as a result of diagnostic imaging in patients with lymphoma. *Clin Transl Oncol* 2016;18:533-6. doi: 10.1007/s12094-015-1394-8. Epub 2015 Aug 26. <https://link.springer.com/article/10.1007%2Fs12094-015-1394-8>.
 16. Dann EJ, Bairey O, Bar-Shalom R, et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. *Br J Haematol* 2017;178:709-18. doi: 10.1111/bjh.14734. Epub 2017 Jun 7.
<https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.14734>.
 17. Dann EJ, Berkahn L, Mashiach T, et al. Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. *Br J Haematol* 2014;164:694-700.
<https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12687>.
 18. Deau B, Franchi P, Briere J, et al. PET2-driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP. *British journal of haematology* 2015;170:278-81. <https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13287>.
 19. Duhresen U, Muller S, Hertenstein B, et al. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2018;36:2024-34.
<https://www.ncbi.nlm.nih.gov/pubmed/29750632>.
 20. Engert A, Goergen H, Markova J, et al. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group. *HemaSphere* 2017;1:e5.
https://journals.lww.com/hemasphere/Fulltext/2017/12000/Reduced_Intensity_Chemotherapy_in_Patients_With.5.aspx.
 21. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *Lancet (London, England)* 2012;379:1791-9.
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(11\)61940-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext).
 22. Epperla N, Shah N, Hamadani M, et al. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.

- Clin Lymphoma Myeloma Leuk 2016;16:672-8. doi: 10.1016/j.clml.2016.08.018. Epub Aug 29. [https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650\(16\)30493-1/fulltext](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(16)30493-1/fulltext).
23. Figura N, Flampouri S, Mendenhall NP, et al. Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. *Adv Radiat Oncol* 2017;2:197-203. doi: 10.1016/j.adro.2017.01.006. eCollection Apr-Jun. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514251/pdf/main.pdf>.
 24. Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30:3368-75. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675665/pdf/zlj3368.pdf>.
 25. Fujiwara H, Maeda Y, Nawa Y, et al. The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma. *European journal of haematology* 2011;87:123-9. <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0609.2011.01645.x>.
 26. Gallamini A, Tarella C, Viviani S, et al. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. *J Clin Oncol* 2018;36:454-62. doi: 10.1200/JCO.2017.75.543. Epub 8 Jan 23. <https://www.ncbi.nlm.nih.gov/pubmed/29360414>.
 27. Ganesan P, Rajendranath R, Kannan K, et al. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. *Ann Oncol* 2015;26:1170-4. doi: 10.093/annonc/mdv077. Epub 2015 Feb 20. <https://academic.oup.com/annonc/article/26/6/1170/161429>.
 28. Goske MJ, Frush DP, Brink JA, Kaste SC, Butler PF, Pandharipande PV. Curbing potential radiation-induced cancer risks in oncologic imaging: perspectives from the 'image gently' and 'image wisely' campaigns. *Oncology (Williston Park)* 2014;28:232-8, 43. <https://www.ncbi.nlm.nih.gov/pubmed/24855732>.
 29. Grellier JF, Vercellino L, Leblanc T, et al. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. *European journal of nuclear medicine and molecular imaging* 2014;41:2023-30. <https://link.springer.com/article/10.1007%2Fs00259-014-2825-4>.
 30. Guttikonda R, Herts BR, Dong F, Baker ME, Fenner KB, Pohlman B. Estimated radiation exposure and cancer risk from CT and PET/CT scans in patients with lymphoma. *European journal of radiology* 2014;83:1011-5. [https://www.ejradiology.com/article/S0720-048X\(14\)00103-X/fulltext](https://www.ejradiology.com/article/S0720-048X(14)00103-X/fulltext).
 31. Hong J, Kim JH, Lee KH, et al. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. *Leukemia & lymphoma* 2014;55:2312-8. <https://www.tandfonline.com/doi/full/10.3109/10428194.2014.882505>.
 32. Johnson PW. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? *Hematology Am Soc Hematol Educ Program* 2016;2016:316-22. doi: 10.1182/asheducation-2016.1.316. <http://asheducationbook.hematologylibrary.org/content/2016/1/316.full.pdf>.
 33. Kedmi M, Apel A, Davidson T, et al. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic

- Complete Remission on Interim FDG-PET/CT Scan. *Acta haematologica* 2016;135:156-61. <https://www.ncbi.nlm.nih.gov/pubmed/26588173>.
34. Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. *Cancer* 2018;124:3210-9. <https://www.ncbi.nlm.nih.gov/pubmed/29738613>.
 35. Lassmann M, Treves ST, Group ESPDHW. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5. 2008) and the 2010 North American consensus guidelines. *European journal of nuclear medicine and molecular imaging* 2014;41:1036-41. <https://www.ncbi.nlm.nih.gov/pubmed/24599377>.
 36. Metser U, Dudebout J, Baetz T, et al. [(18) F]-FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study. *Cancer* 2017;123:2860-6. doi: 10.1002/cncr.30672. Epub 2017 Mar 13. <https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.30672>.
 37. Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. *Blood* 2017;130:2196-203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5. <http://www.bloodjournal.org/content/130/20/2196.long>.
 38. Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. *Lancet Oncol* 2015;16:284-92. doi: 10.1016/S1473-0166(15)70013-6. Epub 2015 Feb 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1473-0166\(15\)70013-6/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1473-0166(15)70013-6/fulltext).
 39. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood* 2012;119:1665-70. <http://www.bloodjournal.org/content/bloodjournal/119/7/1665.full.pdf>.
 40. Papajik T, Myslivecek M, Skopalova M, et al. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT. *Neoplasma* 2011;58:291-7. <https://www.ncbi.nlm.nih.gov/pubmed/21524147>.
 41. Pardal E, Coronado M, Martin A, et al. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. *Br J Haematol* 2014;167:327-36. <https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.13036>.
 42. Patel V, Buckstein M, Perini R, Hill-Kayser C, Svoboda J, Plastaras JP. Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective. *Leukemia & lymphoma* 2013;54:2168-76. <https://www.ncbi.nlm.nih.gov/pubmed/23331161>.
 43. Paulino AC, Margolin J, Dreyer Z, Teh BS, Chiang S. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma. *Pediatric blood & cancer* 2012;58:860-4. <https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.23273>.
 44. Picardi M, Pugliese N, Cirillo M, et al. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures. *Radiology* 2014;272:262-74. <https://www.ncbi.nlm.nih.gov/pubmed/24708193>.

45. Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. *Annals of oncology : official journal of the European Society for Medical Oncology* 2011;22:671-80. <https://academic.oup.com/annonc/article/22/3/671/258222>.
46. Pingali SR, Jewell SW, Havlat L, et al. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. *Cancer* 2014;120:2122-9. <https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.28698>.
47. Pommier P, Dussart S, Girinsky T, et al. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study. *International journal of radiation oncology, biology, physics* 2011;79:823-8. [https://www.redjournal.org/article/S0360-3016\(09\)03622-0/fulltext](https://www.redjournal.org/article/S0360-3016(09)03622-0/fulltext).
48. Press OW, Li H, Schoder H, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. *J Clin Oncol* 2016;34:2020-7. doi: 10.1200/JCO.2015.63.1119. Epub 2016 Apr 11. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513/pdf/JCO631119.pdf>.
49. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med* 2015;372:1598-607. doi: 10.056/NEJMoa1408648. <https://www.ncbi.nlm.nih.gov/pubmed/25901426>.
50. Radiation Dose in X-Ray and CT Exams. 2018. (Accessed August 20, 2018, at <https://www.radiologyinfo.org/en/info.cfm?pg=safety-xray>.)
51. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. *Journal of clinical oncology* 2014;32:1188-94. <http://www.forskningssdatabasen.dk/en/catalog/267014942>.
52. Rathore N, Eissa HM, Margolin JF, et al. Pediatric Hodgkin lymphoma: are we over-scanning our patients? *Pediatric hematology and oncology* 2012;29:415-23. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685486/pdf/nihms478030.pdf>.
53. Robertson VL, Anderson CS, Keller FG, et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma. *International journal of radiation oncology, biology, physics* 2011;80:324-32. [https://www.redjournal.org/article/S0360-3016\(10\)00224-5/pdf](https://www.redjournal.org/article/S0360-3016(10)00224-5/pdf).
54. Romano A, Parrinello NL, Vetro C, et al. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. *Ann Hematol* 2018;97:1009-18. doi: 10.7/s00277-018-3276-y. Epub 2018 Feb 14. <https://link.springer.com/article/10.1007%2Fs00277-018-3276-y>.
55. Sohn BS, Yoon DH, Kim KP, et al. The role of (1)(8)F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin's lymphoma patients. *Annals of hematology* 2013;92:1369-77. <https://link.springer.com/article/10.1007%2Fs00277-013-1782-5>.

56. Stewart DA, Kloiber R, Owen C, et al. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. *Leukemia & Lymphoma* 2014;55:2064-70.
<https://www.tandfonline.com/doi/full/10.3109/10428194.2013.862242>.
57. Straus DJ, Jung S-H, Pitcher B, et al. CALBG 50604: risk-adapted treatment of non-bulky early stage Hodgkin lymphoma based on interim PET. *Blood* 2018;blood-2018-01-827246.
<https://www.ncbi.nlm.nih.gov/pubmed/30049811>.
58. Swinnen LJ, Li H, Quon A, et al. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). *Br J Haematol* 2015;170:56-65. doi: 10.1111/bjh.13389. Epub 2015 Mar 30.
<https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.13389>.
59. Taghipour M, Marcus C, Jones S, Sarangi R, Trahan TJ, Subramaniam RM. The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma. *Nuclear medicine communications* 2016b;37:699-704.
<https://www.ncbi.nlm.nih.gov/pubmed/26990623>.
60. Taghipour M, Marcus C, Nunna P, Subramaniam RM. Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management. *Clin Nucl Med* 2016a;41:e93-7. <https://www.ncbi.nlm.nih.gov/pubmed/26545018>.
61. Terezakis SA, Schoder H, Kowalski A, et al. The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. *Int J Radiat Oncol Biol Phys* 2014;89:376-83. doi: 10.1016/j.ijrobp.2014.02.006. Epub Apr 11.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568241/pdf/nihms738459.pdf>.
62. van Hamersvelt HP, Kwee TC, Fijnheer R, Beek FJ, de Klerk JM, Nievelstein RA. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma? *Journal of computer assisted tomography* 2014;38:620-5.
<https://insights.ovid.com/pubmed?pmid=24681861>.
63. Zabrocka E, Sierko E, Wojtukiewicz MZ. Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience. *Adv Clin Exp Med* 2016;25:1185-92.
<https://www.ncbi.nlm.nih.gov/pubmed/28028972>.
64. Zinzani PL, Broccoli A, Casadei B, et al. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. *Hematological oncology* 2015;33:145-50.
<https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2172>.
65. Zinzani PL, Broccoli A, Gioia DM, et al. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. *J Clin Oncol* 2016;34:1376-85. doi: 10.200/JCO.2015.63.0699. Epub 2016 Feb 16.
<https://iris.unito.it/retrieve/handle/2318/1659393/387895/jco.2015.63.0699.pdf>.

PET Studies Excluded at Full Text

1. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. *N Engl J Med* 2013;368:1408-16. <https://www.ncbi.nlm.nih.gov/pubmed/23574119>.
2. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2014;32:3651-8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220044/pdf/zlj3651.pdf>.
3. Hagtvedt T, Seierstad T, Lund KV, et al. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma. *Acta radiologica (Stockholm, Sweden : 1987)* 2015;56:152-8. <https://www.ncbi.nlm.nih.gov/pubmed/24585944>.
4. Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy. *Leukemia & lymphoma* 2017;22:1-7. <https://academic.oup.com/annonc/article/22/3/671/258222>.
5. Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. *Cancer* 2018;124:3210-9. <https://www.ncbi.nlm.nih.gov/pubmed/29738613>.
6. Kobe C, Kuhnert G, Kahraman D, et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2014;32:1776-81. <https://www.ncbi.nlm.nih.gov/pubmed/24799482>.
7. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. *European journal of nuclear medicine and molecular imaging* 2011;38:1064-71. <https://link.springer.com/article/10.1007%2Fs00259-011-1741-0>.
8. Melani C, Advani R, Roschewski M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. *Haematologica* 2018;103:1337-44. <https://www.ncbi.nlm.nih.gov/pubmed/29748435>.
9. Nasser QJ, Pfeiffer ML, Romaguera J, et al. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. *Leukemia & lymphoma* 2014;55:1013-7. <https://www.tandfonline.com/doi/full/10.3109/10428194.2013.826353>.
10. Papajik T, Myslivecek M, Sedova Z, et al. Synchronous second primary neoplasms detected by initial staging F-18 FDG PET/CT examination in patients with non-Hodgkin lymphoma. *Clinical nuclear medicine* 2011;36:509-12. <https://insights.ovid.com/pubmed?pmid=21637049>.
11. Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. *Annals of oncology : official journal of the European Society for Medical Oncology* 2011;22:671-80. <https://www.ncbi.nlm.nih.gov/pubmed/20693297>.

12. Puchalski AL, Magill C. Imaging Gently. *Emerg Med Clin North Am* 2018;36:349-68. <https://www.ncbi.nlm.nih.gov/pubmed/29622327>.
13. Simontacchi G, Filippi AR, Ciammella P, et al. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. *Int J Radiat Oncol Biol Phys* 2015;92:1077-83. doi: 10.16/j.ijrobp.2015.04.021. Epub Apr 17. [https://www.redjournal.org/article/S0360-3016\(15\)00421-6/fulltext](https://www.redjournal.org/article/S0360-3016(15)00421-6/fulltext).
14. Stieglitz E, Dinh T, Phelps AS, Pampaloni MH, Olshen AB, Robbins E. ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients. *J Pediatr Hematol Oncol* 2018;40:290-4. doi: 10.1097/MPH.0000000000001094. <https://insights.ovid.com/pubmed?pmid=29432308>.
15. Taghipour M, Marcus C, Sheikhbahei S, et al. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up (18)F-FDG PET/CT Scans in Oncology Patients. *J Nucl Med* 2017;58:737-43. doi: 10.2967/jnumed.116.183111. Epub 2016 Nov 3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414499/pdf/737.pdf>.
16. Tai WM, Quah D, Yap SP, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients. *Leukemia & lymphoma* 2011;52:604-12. <https://www.tandfonline.com/doi/full/10.3109/10428194.2010.550073>.
17. Terezakis SA, Hunt MA, Kowalski A, et al. [(1)(8)F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. *International journal of radiation oncology, biology, physics* 2011;81:615-22. <https://www.ncbi.nlm.nih.gov/pubmed/20933343>.
18. Torok JA, Wu Y, Chino J, et al. Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma. *Anticancer Res* 2018;38:2875-81. doi: 10.21873/anticancer.12533. <https://www.ncbi.nlm.nih.gov/pubmed/29715111>.
19. Zabrocka E, Sierko E, Wojtukiewicz MZ. Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience. *Adv Clin Exp Med* 2016;25:1185-92. <https://www.ncbi.nlm.nih.gov/pubmed/28028972>.